SPB3_HUMAN SCCA1 ELISA tesk kit
- Known as:
- SPB3_HUMAN SCCA1 Enzyme-linked immunosorbent assay test tesk reagent
- Catalog number:
- gen17316
- Product Quantity:
- 1
- Category:
- Peptides
- Supplier:
- Other suppliers
- Gene target:
- SPB3_HUMAN SCCA1 ELISA tesk kit
Related genes to: SPB3_HUMAN SCCA1 ELISA tesk kit
- Gene:
- SERPINB3 NIH gene
- Name:
- serpin family B member 3
- Previous symbol:
- SCC, SCCA1
- Synonyms:
- T4-A, HsT1196
- Chromosome:
- 18q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-15
- Date modifiied:
- 2016-10-05
- Gene:
- SERPINB4 NIH gene
- Name:
- serpin family B member 4
- Previous symbol:
- SCCA2
- Synonyms:
- PI11, LEUPIN, SCCA-2, SCCA1
- Chromosome:
- 18q21.33
- Locus Type:
- gene with protein product
- Date approved:
- 1995-09-15
- Date modifiied:
- 2016-04-06
Related products to: SPB3_HUMAN SCCA1 ELISA tesk kit
Related articles to: SPB3_HUMAN SCCA1 ELISA tesk kit
- Squamous cell carcinoma antigen (SCC-Ag) and carcinoembryonic antigen (CEA) are routinely monitored after definitive chemoradiotherapy (dCRT) for esophageal squamous cell carcinoma (ESCC) in Japan, but their clinical significance remains unclear. - Source: PubMed
Sakanaka KatsuyukiKato KenMachida RyunosukeIto YoshinoriDaiko HiroyukiKajiwara TakeshiTsubosa YasuhiroMinashi KeikoAbe TetsuyaKojima TakashiHara HirokiKawakubo HirofumiTsunoda ShigeruWatanabe MasayaDoki YuichiroNagatani YoshiakiKimura YasueSasaki KeitaTakeuchi HiroyaKitagawa Yuko - Lymph node metastasis (LNM) is an important prognostic factor of cervical cancer, significantly impacting patient outcomes and treatment strategies. Current methods for predicting LNM after surgery are limited, necessitating the identification of reliable biomarkers. This study aimed to evaluate the diagnostic value of serum squamous cell carcinoma antigen (SCC-Ag) combined with cytokeratin fragment 21-1 (CYFRA 21-1) for identifying long-term LNM after cervical cancer surgery. - Source: PubMed
Xu KaizhenZhang Guilan - To identify predictive biomarkers for immunotherapy response in advanced/recurrent cervical cancer by evaluating peripheral blood indicators including T-cell subsets and serum biomarkers. This prospective study (June 2022-July 2024) enrolled 50 patients with stage III-IVa or recurrent cervical cancer receiving first-line immunotherapy combined with chemo/radiotherapy from Qingdao Central Hospital network. We analyzed baseline CD4/CD8 T-cell percentages and post-treatment (after one course) levels of CA125, SCCA, T-cell subsets, and PD-1 expression on T-cells using logistic regression (treatment efficacy，comparing 36 responders vs. 14 non-responders) and Cox regression (prognosis, with disease progression or death events occurring in 26 patients). Treatment response was significantly associated with: (1) baseline CD4 T-cell percentage and (2) post-treatment CA125/SCCA levels, CD8 T-cell percentage, and PD-1 expression on both CD4+/CD8+ T-cells (all < .05). Prognostic factors identified by Cox regression included these same markers plus post-treatment CD4 T-cell percentage. Optimal responders showed: high baseline CD4 T-cells, low post-treatment CA125/SCCA, elevated CD4/CD8 T-cells, and reduced PD-1 expression. Peripheral T-cell subsets and serum biomarkers show significant associations with predicted immunotherapy outcomes. High baseline CD4 T-cells with post-treatment normalization of immune markers (increased T-cells, decreased PD-1+ cells, and tumor antigens) are associated with a higher likelihood of benefiting from immunotherapy. It should be noted that this study has limitations, including a modest sample size and the assessment of biomarkers at only a single post-treatment time point, which may affect the generalizability of the findings. These peripheral blood biomarkers may represent a minimally invasive approach for exploring treatment dynamics and are considered worthy of further investigation as potential adjuncts in the context of personalized immunotherapy for advanced cervical cancer. However, their predictive performance and clinical utility remain to be validated in larger, independent cohorts before any clinical application can be considered. - Source: PubMed
Publication date: 2026/06/23
Bai JingCui Xiao-LiBo Si-JiaSun Li - To evaluate the serum expression of SerpinB3/B4/B10 and serum level of interleukin-17 as biomarkers for chronic rhinosinusitis with nasal polyps. - Source: PubMed
Publication date: 2026/05/26
Hussein Hossam AdelHabieb Mona SHamdan Ahmad M - Penile cancer is a rare malignancy, and multicenter data evaluating prognostic biomarkers in the Japanese population are limited. This study aimed to assess the prognostic significance of pretreatment blood-based biomarkers in patients with penile cancer. - Source: PubMed
Tatarano ShuichiMiyake MakitoOsaki YuDaizumoto KeiWada KoichiroKobayashi KeitaKato MinoruFukuhara HideoTsujino TakuyaKobatake KoheiTaoka RikiyaFurukawa JunyaOgawa KoheiShiraishi KojiMatsue TaisukeInoue KeijiMaenosono RyoichiSekino YoheiFujimoto KiyohideEnokida Hideki